Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system. Issue 4 (8th May 2014)

• Record Type: Journal Article
• Authors: Pirovano, Gianpaolo; Kirchin, Miles A.; Lorusso, Vito; Patel, Rutu; Shen, Ningyan
• Is Part Of: Journal of magnetic resonance imaging. Volume 41:Issue 4(2015)
• Page Start: 1096
• Page End: 1103
• Publication Date: 2014-05-08
• Subjects: Magnetic resonance imaging -- Periodicals; 616
• DOI: 10.1002/jmri.24653
• Languages: English
• ISSNs: 1053-1807

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jmri24653-sec-0001" sec-type="section"> <title>Purpose</title> <p>To determine the pharmacokinetic profile of gadobenate dimeglumine in children aged between 2 and 5 years.</p> </sec> <sec id="jmri24653-sec-0002" sec-type="section"> <title>Materials and Methods</title> <p>Fifteen children scheduled to undergo contrast‐enhanced MRI for suspected disease of the central nervous system received a single intravenous injection of 0.1 mmol/kg gadobenate dimeglumine. Children were stratified into three age groups: 2 to <3 years, 3 to <4 years, and 4 to 5 (i.e., <6 years). Serial blood and urine samples collected at prespecified time‐points before and after contrast administration were analyzed for gadolinium concentrations. Pharmacokinetic parameters were calculated using noncompartmental and compartmental techniques.</p> </sec> <sec id="jmri24653-sec-0003" sec-type="section"> <title>Results</title> <p>Mean values of 65.7 μg/mL for highest blood gadolinium concentration, 0.2 L/h/kg for blood clearance, 0.32 L/kg for steady‐state volume of distribution, and 1.2 h for terminal elimination half‐life were determined across all age groups combined. On average, more than 80% of the dose was eliminated in the urine during the first 24 h after administration. All pharmacokinetic parameters were similar between age groups and no effects of gender were noted. No adverse events considered related to gadobenate dimeglumine administration were reported.</p> </sec> <sec id="jmri24653-sec-0004" sec-type="section"> <title>Conclusion</title> <p>In terms of pharmacokinetic profile no dosage adjustment from the approved adult gadobenate dimeglumine dose of 0.1 mmol/kg bodyweight is necessary in children aged between 2 and 5 years. <bold>J. Magn. Reson. Imaging 2015;41:1096–1103</bold>. © <bold>2014 Wiley Periodicals, Inc</bold>.</p> </sec> </abstract>